Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALT Altimmune, Inc.

Trading 03-19 15:16:36 EDT

3.49

+0.07

+1.90%

High3.51	Low3.34	Vol1.76M
Open3.38	D1 Closing3.42	Amplitude4.97%
Mkt Cap453.29M	Tradable Cap432.14M	Total Shares130.07M
T/O6.02M	T/O Rate1.42%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":3.485,"timestamp":1773947792397,"preClose":3.42,"halted":0,"volume":1758149,"delay":0,"changeRate":0.01900584795321636,"floatShares":124000000,"shares":130070000,"eps":-0.999873,"marketStatus":"Trading","change":0.065,"latestTime":"03-19 15:16:36 EDT","open":3.38,"high":3.51,"low":3.34,"amount":6020588.9089994,"amplitude":0.049708,"askPrice":3.49,"askSize":2006,"bidPrice":3.48,"bidSize":1859,"shortable":3,"etf":0,"ttmEps":-0.999873,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773950400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.42,"preHourTrading":{"tag":"盘前","latestPrice":3.4,"preClose":3.42,"latestTime":"09:26 EDT","volume":32865,"amount":111530.6804325,"timestamp":1773926780262,"change":-0.02,"changeRate":-0.005848,"amplitude":0.01731},"postHourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.42,"latestTime":"19:55 EDT","volume":186600,"amount":641884.4045,"timestamp":1773878139700,"change":0.04,"changeRate":0.011696,"amplitude":0.024386},"volumeRatio":0.670407,"impliedVol":0.9116,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/ALT/tweets","defaultTab":"tweets","newsList":[{"id":"2620324495","title":"Altimmune Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2620324495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620324495?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:08","pubTimestamp":1773918526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALT","BK4599","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2620416452","title":"Truist Initiates Altimmune at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620416452","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620416452?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:45","pubTimestamp":1773917112,"startTime":"0","endTime":"0","summary":"Altimmune (ALT) has an average rating of overweight and mean price target of $19.89, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"gpt_icon":0},{"id":"2620211462","title":"U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKesson","url":"https://stock-news.laohu8.com/highlight/detail?id=2620211462","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620211462?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:52","pubTimestamp":1773903174,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKessonMarch 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL4N4070JZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNDM","KNSL","CNC","CEGX","PAYX","FWONK","CAH","CTEV","CTMX","TLN","GIS","SAIL","CCL.UK","MCK","MRK","CCRN","SJM","MUU","JBL","CNCG","LU1803068979.SGD","ALXO","BRX","HTFL","IBM","IVT","AJG","FIVE","JAZZ","LU2461242641.AUD","MUD","WSM","LU2065171311.SGD","MULL","COR","CCL","ALT","SHW","CLF","ENS","PGR","MU","HQY","DNTH","FRT","CYTK","CEG","LU0310799852.SGD","BBIO"],"gpt_icon":1},{"id":"2620621382","title":"Altimmune initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2620621382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620621382?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:00","pubTimestamp":1773864019,"startTime":"0","endTime":"0","summary":"Truist initiated coverage of Altimmune (ALT) with a Buy rating and $12 price target The firm believes that Altimmune’s lead asset, pemvidutide, “co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/altimmune-initiated-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/altimmune-initiated-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1878469433.USD","ALT","BK4599"],"gpt_icon":0},{"id":"2620401181","title":"Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401181","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401181?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779400,"startTime":"0","endTime":"0","summary":"Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257672/0/en/Immunocore-will-present-five-year-overall-survival-data-for-KIMMTRAK-during-oral-presentation-at-the-2026-AACR-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4006","BK4187","IE0031619046.USD","LU1878469433.USD","BK4599","IE00B7SZL793.SGD","OS","LU2065731478.USD","CRS","BK4097","LU0963586101.USD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4139"],"gpt_icon":0},{"id":"2620846727","title":"Altimmune Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620846727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620846727?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:27","pubTimestamp":1773678420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:27 ET (16:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2618922463","title":"Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922463","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922463?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:01","pubTimestamp":1773248460,"startTime":"0","endTime":"0","summary":"- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3254054/0/en/Solid-Biosciences-Provides-Interim-Positive-Clinical-Update-on-Phase-1-2-INSPIRE-DUCHENNE-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","BK4599","FA","BK4539","SLDB","BK4139","BK4535","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2618628001","title":"Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628001?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"NEW YORK, March  09, 2026  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies ev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251730/8790/en/Data-Published-in-Neurology-and-Therapy-Demonstrate-Significant-Reductions-in-Relapse-and-MRI-Activity-with-BRIUMVI-in-People-with-Highly-Active-Relapsing-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","LU0882574139.USD","LU2271345857.HKD","ALT","LU0158827948.USD","LU0971096721.USD","LU0106831901.USD","LU0528227936.USD","BK4139","LU0912757837.SGD","LU1989772840.SGD","LU1791710400.SGD","LU1668664300.SGD","LU1720051108.HKD","BK4588","ARR","CNS","LU1244550577.SGD","BK4581","LU1791710582.SGD","LU2023251221.USD","BK4599","LU2357305700.SGD","BK4534","LU0795875086.SGD","IE00BKVL7J92.USD","LU2111349929.HKD","LU2133065610.SGD","LU1244550221.USD","LU0795875169.SGD","LU0006306889.USD","LU0158827781.USD","HCP","LU0106261372.USD","LU2089284900.SGD","LU0314104364.USD","LU0098860793.USD","PML","LU1363072403.SGD","BK4127","LU0234570918.USD","LU1162221912.USD","LU1244550494.USD","LU2347655156.SGD","LU1732799900.SGD","TGTX","IE00BZ1G4Q59.USD","LU0557290698.USD","BK4504","LU2028103732.USD"],"gpt_icon":0},{"id":"2617631435","title":"Altimmune Is Maintained at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2617631435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617631435?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:32","pubTimestamp":1772814720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 11:32 ET (16:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU1878469433.USD","BK4139","ALT"],"gpt_icon":0},{"id":"2617638398","title":"B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638398","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617638398?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:14","pubTimestamp":1772802841,"startTime":"0","endTime":"0","summary":"Altimmune (ALT) has an average rating of overweight and mean price target of $19.12, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4599","ALT","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2617680763","title":"Altimmune Inc. Announces 2026 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680763?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:02","pubTimestamp":1772802172,"startTime":"0","endTime":"0","summary":"Altimmune, Inc. will hold its 2026 annual meeting virtually on April 16, 2026. Stockholders will vote on the election of nine directors and the ratification of Ernst & Young LLP as independent registered public accounting firm for 2026. The meeting will also include an advisory vote on executive compensation and a proposal to amend the company’s certificate of incorporation to increase authorized common shares from 200 million to 400 million. In addition, stockholders will vote on an amendment to the 2019 Employee Stock Purchase Plan to increase the share reserve from 403,500 to 1,108,827, and on authorization to adjourn the meeting if needed to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL85VBs4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4599","BK4139","ALT"],"gpt_icon":0},{"id":"2617668076","title":"Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617668076?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802000,"startTime":"0","endTime":"0","summary":"-- Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial. ovarian cancer patients with a TP53 Y220C mutation. -- Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug. Administration for the treatment of TP53 Y220C positive ovarian cancer. -- New England Journal of Medicine published first-in-human rezatapopt data. showing selective reactivation of mutant p53 in advanced solid tumors. -- Cash, cash equivalents, and marketable securities of $112.9 million as of. December 31, 2025 providing expected cash runway to end of second quarter. PRINCETON, N.J., March 06, 2026  -- PMV Pharmaceuticals, Inc. , a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.clinical trial. The multicenter, single-arm, registrational Phase 2 study. is assessing rezatapopt as monotherapy at a dose of 2000 mg once-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4183","BK4599","PMVP","LU1878469433.USD","IE0009354923.USD","ORR","ODD","BK4139"],"gpt_icon":0},{"id":"2617578672","title":"Altimmune Shares Fall After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578672","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617578672?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:11","pubTimestamp":1772737873,"startTime":"0","endTime":"0","summary":"Altimmune (ALT) shares were down about 12% in Thursday trading after the clinical-stage drugmaker reported a wider-than-expected Q4 loss.Earlier, the company posted a Q4 net loss of $0.27 per diluted ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1878469433.USD","ALT","BK4599","BK4139"],"gpt_icon":0},{"id":"2617278005","title":"BUZZ-Altimmune falls after posting quarterly revenue below estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617278005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617278005?lang=en_us&edition=fundamental","pubTime":"2026-03-06 01:41","pubTimestamp":1772732487,"startTime":"0","endTime":"0","summary":"BUZZ-Altimmune falls after posting quarterly revenue below estimates** Shares of drug developer Altimmune ALT.O fall 8.9% to $3.89** Co reports Q4 loss of 27 cents/shr vs analysts' average estimate of 24 cents/shr - data compiled by LSEG ** Says Q4 revenue was $26,000 vs estimate of $700,000** Shares down 50% in 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL4N3ZT1RE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4139","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2617524542","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617524542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617524542?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:30","pubTimestamp":1772728250,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Altimmune (ALT – Research Report), Rhythm Pharmaceuticals (RYTM –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-altimmune-alt-rhythm-pharmaceuticals-rytm-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-altimmune-alt-rhythm-pharmaceuticals-rytm-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","CRMD","BK4585","BK4588","RYTM","LU1878469433.USD","BK4137","LU0029874061.USD","LU0128526141.USD","XBI","HCSG","BK4599","LABU","BK4139","BK4007","ALT","XLV"],"gpt_icon":0},{"id":"2617544147","title":"Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544147","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544147?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:27","pubTimestamp":1772713640,"startTime":"0","endTime":"0","summary":"Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year.  The company reported $26.000 thousand in sales","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51062608/altimmune-q4-eps-0-27-up-from-0-33-yoy-sales-26-000k-up-from-5-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU1878469433.USD","BK4139","ALT"],"gpt_icon":0},{"id":"2617541058","title":"Altimmune Q4 revenue beats, EPS misses estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541058","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541058?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:10","pubTimestamp":1772712636,"startTime":"0","endTime":"0","summary":"Altimmune Q4 revenue beats, EPS misses estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectationsQ4 EPS and net income missed analyst estimatesCompany strengthened balance sheet wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0KL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4599","LU1878469433.USD","ALT"],"gpt_icon":0},{"id":"2617541639","title":"Altimmune Q4 Operating Expenses USD 28.919 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541639?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLX2194E2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","ALT","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2617415745","title":"Altimmune Q4 Basic EPS USD -0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2617415745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617415745?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLX2194E2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4139","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2617545487","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2617545487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617545487?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:00","pubTimestamp":1772708400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CPI Card Grp                                    4Q       .65   7:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BURL","BVS","ACCO","FCEL","AMTX","BRLT","COST","BNTX","AMBQ","CLAR","AKA","ADCT","ABM","ARQ","ASMB","CHRS","ATHM","ALT","CTNM","CRVS","COO","BJ","CGEM","CANG","AEYE","CTOS","ALNT","AMPX","CNQ","CCEC","COOK","ACET","AQN","ALGS","BETA","CRMD","CLYM","BODI","CASY","APYX","BBCP","OLPX","CING","BTAI","ANNX","BLND","BCIC","CIEN"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.altimmune.com","stockEarnings":[{"period":"1week","weight":-0.1},{"period":"1month","weight":-0.245},{"period":"3month","weight":-0.3228},{"period":"6month","weight":-0.0952},{"period":"1year","weight":-0.3904},{"period":"ytd","weight":-0.0526}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.421053,"avgChangeRate":0.021325},{"month":2,"riseRate":0.368421,"avgChangeRate":-0.012068},{"month":3,"riseRate":0.368421,"avgChangeRate":-0.060528},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.049636},{"month":5,"riseRate":0.5,"avgChangeRate":0.064208},{"month":6,"riseRate":0.388889,"avgChangeRate":-0.000157},{"month":7,"riseRate":0.388889,"avgChangeRate":0.041853},{"month":8,"riseRate":0.444444,"avgChangeRate":0.10411},{"month":9,"riseRate":0.210526,"avgChangeRate":-0.115822},{"month":10,"riseRate":0.263158,"avgChangeRate":0.032599},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.007448},{"month":12,"riseRate":0.526316,"avgChangeRate":0.184275}],"exchange":"NASDAQ","name":"Altimmune, Inc.","nameEN":"Altimmune, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Altimmune, Inc.,ALT,Altimmune, Inc.股票,Altimmune, Inc.股票老虎,Altimmune, Inc.股票老虎国际,Altimmune, Inc.行情,Altimmune, Inc.股票行情,Altimmune, Inc.股价,Altimmune, Inc.股市,Altimmune, Inc.股票价格,Altimmune, Inc.股票交易,Altimmune, Inc.股票购买,Altimmune, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}